All In Biotech

Drug Trial Radar · NCT06230224

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

216

Actual

Start

Feb 15, 2024

Primary completion

May 29, 2028

Study completion May 29, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug versus Standard of Care (SOC) * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities

Conditions

  • B-Cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

  • OdronextamabDrug

    Administered by intravenous (IV) infusion

  • IfosfamideDrug

    Administered by IV infusion, as part of the ICE ± R salvage therapy

  • CarboplatinDrug

    Administered by IV infusion, as part of the ICE ± R salvage therapy

  • EtoposideDrug

    Administered by IV infusion, as part of the ICE ± R salvage therapy

  • RituximabDrug

    Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.

  • DexamethasoneDrug

    Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.

  • CisplatinDrug

    Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.

  • CytarabineDrug

    Administered by IV infusion, as part of the DHAP ± R salvage therapy.

  • GemcitabineDrug

    Administered by IV infusion, as part of the GDP ± R salvage therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS) as assessed by independent central review (ICR)Time frame: Assessed up to 3 years

Locations

81 sites in 14 countries. Site status is shown where the registry gives one.

  • Sanatorio Allende

    Córdoba, Argentina

  • Hospital Privado Universitario de Cordoba

    Córdoba, Argentina

  • Hospital Aleman

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Fundaleu - Fundacion Para Combatir La Leucemia

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Hospital Alta Complejidad El Cruce

    San Juan Bautista, Buenos Aires, Argentina

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Olivia Newton John Cancer Wellness & Research Centre

    Heidelberg, Victoria, Australia

  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil

  • Hospital Sirio Libanes

    São Paulo, Brazil

  • A Beneficencia Portuguesa de Sao Paulo, Oncology House

    São Paulo, Brazil

  • Instituto D'Or De Pesquisa e Ensino

    São Paulo, Brazil

  • Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo

    São Paulo, Brazil

  • Casa de Saude Santa Marcelina

    São Paulo, Brazil

  • Hospital Santa Izabel - Santa Casa de Misericordia da Bahia

    Salvador, Estado de Bahia, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Ensino e Terapia de Inovacao Clinica Amo (Etica)

    Salvador, Estado de Bahia, Brazil

  • Hospital Sirio Libanes Brasilia

    Brasília, Federal District, Brazil

  • Uopeccan Hospital do Cancer de Cascavel

    Cascavel, Paraná, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro Gaucho Integrado

    Porto Alegre, Rio Grande do Sul, Brazil

  • Amaral Carvalho Hospital

    Jaú, São Paulo, Brazil

  • Fundacion Arturo Lopez Perez

    Santiago, Santiago Metropolitan, Chile

  • Clinica Alemana de Santiago

    Santiago, Santiago Metropolitan, Chile

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia, Colombia

  • Clinica Imbanaco

    Cali, Valle del Cauca Department, Colombia

  • Semmelweis University

    Budapest, Hungary

  • University of Pecs

    Pécs, Baranya, Hungary

  • Debreceni Egyetem

    Debrecen, Hajdú-Bihar, Hungary

  • Hospital Sultanah Aminah Jhor Bahru

    Johor Bahru, Johor, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Kuala Lumpur, Malaysia

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, Malaysia

  • Hospital Ampang

    Kuala Lumpur, Selangor, Malaysia

  • Subang Jaya Medical Center

    Subang Jaya, Selangor, Malaysia

  • Coltea Clinical Hospital

    Bucharest, Bucharest, Romania

  • Ion Chiricuta Oncology Institute

    Cluj-Napoca, Cluj, Romania

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.